#615396
Table of Contents
A number sign (#) is used with this entry because of evidence that left ventricular noncompaction-10 (LVNC10) and dilated cardiomyopathy-1MM (CMD1MM) are caused by heterozygous mutation in the MYBPC3 gene (600958) on chromosome 11p11.
Probst et al. (2011) described 2 families with left ventricular noncompaction (LVNC) due to mutations in the MYBPC3 gene (see MOLECULAR GENETICS). In the first family, the male proband presented at age 70 years with dyspnea; family screening revealed that his asymptomatic son was also affected. Both patients had noncompacted segments of the left midventricular inferior and lateral wall. In the second family, the female proband had nonsustained ventricular flutter and received an implantable cardioverter-defibrillator; she had noncompacted segments of the apex and midventricular wall.
In a cohort of 63 unrelated white patients of western European descent with left ventricular noncompaction (LVNC), Probst et al. (2011) analyzed 8 sarcomere genes and identified 5 probands with 4 different heterozygous mutations in the MYBPC3 gene (see, e.g., 600958.0026-600958.0028).
Dilated Cardiomyopathy 1MM
In 46 young patients with dilated cardiomyopathy (CMD), Daehmlow et al. (2002) screened 4 sarcomeric protein genes and identified heterozygosity for a missense mutation in the MYBPC3 gene (N948T; 600958.0013) in 1 patient. Daehmlow et al. (2002) noted that they could not confirm the disease-causing nature of the variant because family members were not available for the calculation of a 2-point lod score and further investigation.
Ehlermann et al. (2008) screened the MYBPC3 gene in 87 patients with hypertrophic cardiomyopathy (see CMH4, 115197) and 71 patients with CMD and identified heterozygous mutations in 16 (18.4%) of the CMH patients and in 2 (2.8%) of the CMD patients. However, in the first CMD family, 3 additional carriers of the MYBPC3 missense mutation had no certain pathologic findings, and the authors noted that in the index patient, hypertensive heart disease could not be ruled out as the cause of his CMD phenotype. In the second CMD family, the 2 oldest carriers of the splice site mutation displayed CMD, whereas 4 younger mutation carriers showed CMH; the authors stated that it was most likely that the 2 older patients suffered from end-stage CMH with progression to a CMD phenotype. Screening of 5 additional cardiomyopathy-associated genes (MYH7, 160760; TNNT2, 191045; TNNI3, 191044; ACTC1, 102540; and TPM1, 191010) revealed no further mutations.
Hershberger et al. (2010) screened 5 cardiomyopathy-associated genes in 312 patients with CMD, who had previously been studied by Hershberger et al. (2008), and identified 12 MYBPC3 variants in 13 (4.2%) of the probands, of which 2 were considered to be 'likely' disease-causing mutations: A833T (600958.0024) and C1264F (600958.0025). The A833T change was identified in affected individuals from 3 families; haplotype analysis suggested a founder mutation. Another mutation, G490R (600958.0026), which had previously been reported in association with hypertrophic cardiomyopathy (van Driest et al., 2004; Morita et al., 2008), was detected in a CMD proband and designated as 'possibly' causative because family members were not available for segregation analysis.
Daehmlow, S., Erdmann, J., Knueppel, T., Gille, C., Froemmel, C., Hummel, M., Hetzer, R., Regitz-Zagrosek, V. Novel mutations in sarcomeric protein genes in dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 298: 116-120, 2002. [PubMed: 12379228, related citations] [Full Text]
Ehlermann, P., Weichenhan, D., Zehelein, J., Steen, H., Pribe, R., Zeller, R., Lehrke, S., Zugck, C., Ivandic, B. T., Katus, H. A. Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene. BMC Med. Genet. 9: 95, 2008. Note: Electronic Article. [PubMed: 18957093, images, related citations] [Full Text]
Hershberger, R. E., Norton, N., Morales, A., Li, D., Siegfried, J. D., Gonzalez-Quintana, J. Coding sequence rare variants identified in MYBPC3, MYH6, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy. Circ. Cardiovasc. Genet. 3: 155-161, 2010. [PubMed: 20215591, related citations] [Full Text]
Hershberger, R. E., Parks, S. B., Kushner, J. D., Li, D., Ludwigsen, S., Jakobs, P., Nauman, D., Burgess, D., Partain, J., Litt, M. Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3 (sic), and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy. Clin. Transl. Sci. 1: 21-26, 2008. [PubMed: 19412328, related citations] [Full Text]
Morita, H., Rehm, H. L., Menesses, A., McDonough, B., Roberts, A. E., Kucherlapati, R., Towbin, J. A., Seidman, J. G., Seidman, C. E. Shared genetic causes of cardiac hypertrophy in children and adults. New Eng. J. Med. 358: 1899-1908, 2008. [PubMed: 18403758, images, related citations] [Full Text]
Probst, S., Oechslin, E., Schuler, P., Greutmann, M., Boye, P., Knirsch, W., Berger, F., Thierfelder, L., Jenni, R., Klaassen, S. Sarcomere gene mutations in isolated left ventricular noncompaction cardiomyopathy do not predict clinical phenotype. Circ. Cardiovasc. Genet. 4: 367-374, 2011. [PubMed: 21551322, related citations] [Full Text]
Van Driest, S. L., Vasile, V. C., Ommen, S. R., Will, M. L., Tajik, A. J., Gersh, B. J., Ackerman, M. J. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 44: 1903-1910, 2004. [PubMed: 15519027, related citations] [Full Text]
Other entities represented in this entry:
ORPHA: 154, 54260; DO: 0081158;
| Location | Phenotype |
Phenotype MIM number |
Inheritance |
Phenotype mapping key |
Gene/Locus |
Gene/Locus MIM number |
|---|---|---|---|---|---|---|
| 11p11.2 | Left ventricular noncompaction 10 | 615396 | Autosomal dominant | 3 | MYBPC3 | 600958 |
| 11p11.2 | Cardiomyopathy, dilated, 1MM | 615396 | Autosomal dominant | 3 | MYBPC3 | 600958 |
A number sign (#) is used with this entry because of evidence that left ventricular noncompaction-10 (LVNC10) and dilated cardiomyopathy-1MM (CMD1MM) are caused by heterozygous mutation in the MYBPC3 gene (600958) on chromosome 11p11.
Probst et al. (2011) described 2 families with left ventricular noncompaction (LVNC) due to mutations in the MYBPC3 gene (see MOLECULAR GENETICS). In the first family, the male proband presented at age 70 years with dyspnea; family screening revealed that his asymptomatic son was also affected. Both patients had noncompacted segments of the left midventricular inferior and lateral wall. In the second family, the female proband had nonsustained ventricular flutter and received an implantable cardioverter-defibrillator; she had noncompacted segments of the apex and midventricular wall.
In a cohort of 63 unrelated white patients of western European descent with left ventricular noncompaction (LVNC), Probst et al. (2011) analyzed 8 sarcomere genes and identified 5 probands with 4 different heterozygous mutations in the MYBPC3 gene (see, e.g., 600958.0026-600958.0028).
Dilated Cardiomyopathy 1MM
In 46 young patients with dilated cardiomyopathy (CMD), Daehmlow et al. (2002) screened 4 sarcomeric protein genes and identified heterozygosity for a missense mutation in the MYBPC3 gene (N948T; 600958.0013) in 1 patient. Daehmlow et al. (2002) noted that they could not confirm the disease-causing nature of the variant because family members were not available for the calculation of a 2-point lod score and further investigation.
Ehlermann et al. (2008) screened the MYBPC3 gene in 87 patients with hypertrophic cardiomyopathy (see CMH4, 115197) and 71 patients with CMD and identified heterozygous mutations in 16 (18.4%) of the CMH patients and in 2 (2.8%) of the CMD patients. However, in the first CMD family, 3 additional carriers of the MYBPC3 missense mutation had no certain pathologic findings, and the authors noted that in the index patient, hypertensive heart disease could not be ruled out as the cause of his CMD phenotype. In the second CMD family, the 2 oldest carriers of the splice site mutation displayed CMD, whereas 4 younger mutation carriers showed CMH; the authors stated that it was most likely that the 2 older patients suffered from end-stage CMH with progression to a CMD phenotype. Screening of 5 additional cardiomyopathy-associated genes (MYH7, 160760; TNNT2, 191045; TNNI3, 191044; ACTC1, 102540; and TPM1, 191010) revealed no further mutations.
Hershberger et al. (2010) screened 5 cardiomyopathy-associated genes in 312 patients with CMD, who had previously been studied by Hershberger et al. (2008), and identified 12 MYBPC3 variants in 13 (4.2%) of the probands, of which 2 were considered to be 'likely' disease-causing mutations: A833T (600958.0024) and C1264F (600958.0025). The A833T change was identified in affected individuals from 3 families; haplotype analysis suggested a founder mutation. Another mutation, G490R (600958.0026), which had previously been reported in association with hypertrophic cardiomyopathy (van Driest et al., 2004; Morita et al., 2008), was detected in a CMD proband and designated as 'possibly' causative because family members were not available for segregation analysis.
Daehmlow, S., Erdmann, J., Knueppel, T., Gille, C., Froemmel, C., Hummel, M., Hetzer, R., Regitz-Zagrosek, V. Novel mutations in sarcomeric protein genes in dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 298: 116-120, 2002. [PubMed: 12379228] [Full Text: https://doi.org/10.1016/s0006-291x(02)02374-4]
Ehlermann, P., Weichenhan, D., Zehelein, J., Steen, H., Pribe, R., Zeller, R., Lehrke, S., Zugck, C., Ivandic, B. T., Katus, H. A. Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene. BMC Med. Genet. 9: 95, 2008. Note: Electronic Article. [PubMed: 18957093] [Full Text: https://doi.org/10.1186/1471-2350-9-95]
Hershberger, R. E., Norton, N., Morales, A., Li, D., Siegfried, J. D., Gonzalez-Quintana, J. Coding sequence rare variants identified in MYBPC3, MYH6, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy. Circ. Cardiovasc. Genet. 3: 155-161, 2010. [PubMed: 20215591] [Full Text: https://doi.org/10.1161/CIRCGENETICS.109.912345]
Hershberger, R. E., Parks, S. B., Kushner, J. D., Li, D., Ludwigsen, S., Jakobs, P., Nauman, D., Burgess, D., Partain, J., Litt, M. Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3 (sic), and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy. Clin. Transl. Sci. 1: 21-26, 2008. [PubMed: 19412328] [Full Text: https://doi.org/10.1111/j.1752-8062.2008.00017.x]
Morita, H., Rehm, H. L., Menesses, A., McDonough, B., Roberts, A. E., Kucherlapati, R., Towbin, J. A., Seidman, J. G., Seidman, C. E. Shared genetic causes of cardiac hypertrophy in children and adults. New Eng. J. Med. 358: 1899-1908, 2008. [PubMed: 18403758] [Full Text: https://doi.org/10.1056/NEJMoa075463]
Probst, S., Oechslin, E., Schuler, P., Greutmann, M., Boye, P., Knirsch, W., Berger, F., Thierfelder, L., Jenni, R., Klaassen, S. Sarcomere gene mutations in isolated left ventricular noncompaction cardiomyopathy do not predict clinical phenotype. Circ. Cardiovasc. Genet. 4: 367-374, 2011. [PubMed: 21551322] [Full Text: https://doi.org/10.1161/CIRCGENETICS.110.959270]
Van Driest, S. L., Vasile, V. C., Ommen, S. R., Will, M. L., Tajik, A. J., Gersh, B. J., Ackerman, M. J. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 44: 1903-1910, 2004. [PubMed: 15519027] [Full Text: https://doi.org/10.1016/j.jacc.2004.07.045]
Dear OMIM User,
To ensure long-term funding for the OMIM project, we have diversified our revenue stream. We are determined to keep this website freely accessible. Unfortunately, it is not free to produce. Expert curators review the literature and organize it to facilitate your work. Over 90% of the OMIM's operating expenses go to salary support for MD and PhD science writers and biocurators. Please join your colleagues by making a donation now and again in the future. Donations are an important component of our efforts to ensure long-term funding to provide you the information that you need at your fingertips.
Thank you in advance for your generous support,
Ada Hamosh, MD, MPH
Scientific Director, OMIM